Bacterial vaginosis: comparative effectiveness of treatments with 5-nitroimidazole derivatives
DOI: 10.32364/2618-8430-2023-6-2-78-87
I.G. Kutsenko, I.O. Borovikov, E.I. Kravtsova, S.K. Batmen, A.S. Magay, O.I. Borovikova, V.A. Avakimyan, A.A. Andreeva
Kuban State Medical University, Krasnodar, Russian Federation
Aim: to perform a comparative analysis of clinical and microbiological efficacy and compliance to treatment with 5-nitroimidazole derivatives in patients with bacterial vaginosis (BV).
Patients and Methods: this prospective open randomized study included 96 patients diagnosed with BV. The patients were divided into two groups: group 1 (n=48) received antimicrobials — oral secnidazole 2000 mg in a single dose (decontamination therapy) and vaginally administered L. casei rhamnosus Doderleini for 14 days to restore the vaginal flora (contamination therapy); group 2 (n=48) received oral metronidazole 500 mg twice daily for 7 days (decontamination therapy) and vaginally administered L. casei rhamnosus Doderleini for 14 days (contamination therapy). Clinical efficacy was evaluated one and six months after the end of therapy. The treatment efficacy criteria included the absence of specific patient's complaints, clinical and laboratory findings (pH; Nugent score), and PCR results. The compliance to treatment was assessed using clinical and psychological tests (the Morisky-Green Scale and the Modified Medication Compliance Scale). The assessment of safety profile was based on the analysis of adverse events (AE).
Results: one month after the end of treatment all patients had a statistically significant (p<0.05) reduction in the prevalence of BV symptoms (unpleasant vaginal odor, pathological vaginal discharge, itching, dyspareunia, dysuria events) as compared to those at the baseline. At month 1 after the end of treatment, subgroup analysis did not demonstrate a significant difference. Six months after the end of treatment the proportion of the group 1 patients who had pathological vaginal discharge with specific odor increased to 16.7%, while in the group 2 patients it reduced to 8.3% (p<0.05). Microbiological assessment (PCR) of the combination therapy in two groups of patients with BV demonstrated a high antibacterial efficacy of 5-nitroimidazole derivatives during the first month of follow-up. The patients were considered fully compliant if they scored 4 on the Morisky — Green Scale and scored 30 on the Modified Medication Compliance Scale of V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology. The percentage of full compliance was 76.2±2.8% in the group 1 patients and 93.75±3.25% in the group 2 patients.
Conclusion: a high comparative clinical and microbiological effectiveness of treatments with 5-nitroimidazole derivatives (metronidazole and secnidazole) with further vaginal colonization with lactobacilli was demonstrated in patients with bacterial vaginosis. Full medication compliance was higher in patients receiving secnidazole for BV treatment.
Keywords: bacterial vaginosis, vaginal microbiota, vaginal discharge, 5-nitroimidazole derivatives, metronidazole, secnidazole, compliance.
For citation: Kutsenko I.G., Borovikov I.O., Kravtsova E.I. et al. Bacterial vaginosis: comparative effectiveness of treatments with 5-nitroimidazole derivatives. Russian Journal of Woman and Child Health. 2023;6(2):78–87 (in Russ.). DOI: 10.32364/2618-8430-2023-6-2-78-87.
About the authors:
Irina I. Kutsenko — Dr. Sc. (Med.), Professor, Head of the Department of Obstetrics, Gynecology and Perinatology, Kuban State Medical University; 4, Mitrofan Sedin str., Krasnodar, 350063, Russian Federation; ORCID iD 0000-0003-0938-8286.
Igor O. Borovikov — Dr. Sc. (Med.), associate professor of the Department of Obstetrics, Gynecology and Perinatology, Kuban State Medical University; 4, Mitrofan Sedin str., Krasnodar, 350063, Russian Federation; ORCID iD 0000-0001-8576-1359.
Elena I. Kravtsova — C. Sc. (Med.), associate professor of the Department of Obstetrics, Gynecology and Perinatology, Kuban State Medical University; 4, Mitrofan Sedin str., Krasnodar, 350063, Russian Federation; ORCID iD 0000-0001-8987-7375.
Saida K. Batmen — C. Sc. (Med.), associate professor of the Department of Obstetrics, Gynecology and Perinatology, Kuban State Medical University; 4, Mitrofan Sedin str., Krasnodar, 350063, Russian Federation; ORCID iD 0000-0002-1790-444X.
Anton S. Magay — postgraduate student of the Department of Obstetrics, Gynecology and Perinatology, Kuban State Medical University; 4, Mitrofan Sedin str., Krasnodar, 350063, Russian Federation; ORCID iD 0000-0003-2910-8798.
Olga I. Borovikova — postgraduate student of the Department of Obstetrics, Gynecology and Perinatology, Kuban State Medical University; 4, Mitrofan Sedin str., Krasnodar, 350063, Russian Federation; ORCID iD 0000-0002-7275-9388.
Veronika A. Avakimyan — C. Sc. (Med.), assistant of the Department of Obstetrics, Gynecology and Perinatology, Kuban State Medical University; 4, Mitrofan Sedin str., Krasnodar, 350063, Russian Federation; ORCID iD 0000-0002-4946-6640.
Anastasiya A. Andreeva — postgraduate student of the Department of Obstetrics, Gynecology and Perinatology, Kuban State Medical University; 4, Mitrofan Sedin str., Krasnodar, 350063, Russian Federation; ORCID iD 0000-0001-5749-4193.
Contact information: Igor O. Borovikov, e-mail: bio2302@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 13.03.2023.
Revised 05.04.2023.
Accepted 28.04.2023.
2. Mendling W., Palmeira-de-Oliveira A., Biber S., Prasauskas V. An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review. Arch Gynecol Obstet. 2019;300(1):1–6. DOI: 10.1007/s00404-019-05142-8.
3. Dobrokhotova Yu.E., Kazantseva V.D., Bondarenko K.R. Bacterial vaginosis: modern anti-relapse strategies. RMJ. 2022;8:61–65 (in Russ.).
4. Faught B.M., Reyes S. Characterization and Treatment of Recurrent Bacterial Vaginosis. J Womens Health (Larchmt). 2019;28(9):1218–1226. DOI: 10.1089/jwh.2018.7383.
5. Krysanova A.A., Gushchin A.E., Savicheva A.M. The importance of determining the genotypes of Gardnerella vaginalis in the diagnosis of recurrent bacterial vaginosis. Medical alphabet. 2021;1(30):48–52 (in Russ.). DOI: 10.33667/2078-5631-2021-30-48-52.
6. Ravel J., Moreno I., Simón C. Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory disease. Am J Obstet Gynecol. 2021;224(3):251–257. DOI: 10.1016/j.ajog.2020.10.019.
7. Ratten L., Plummer E., Murray G. et al. Sex is associated with the persistence of non-optimal vaginal microbiota following treatment for bacterial vaginosis: a prospective cohort study. BJOG. 2021;128(4):756–767. DOI: 10.1111/1471-0528.16430.
8. Marushkina O.I. Therapy of bacterial vaginosis in non-pregnant patients. Meditsinsky Sovet. 2019;7:104–109 (in Russ.). DOI: 10.21518/2079-701X-2019-7-104-109.
9. Redelinghuys M.J., Geldenhuys J., Jung H., Kock M.M. Bacterial Vaginosis: Current Diagnostic Avenues and Future Opportunities. Front Cell Infect Microbiol. 2020;10:354. DOI: 10.3389/fcimb.2020.00354.
10. Widowychenko Y.P., Gopchuk E.N. Bacterial Vaginosis — monotherapy with combined drugs. Zdorov'e zhenshchiny. 2016;1(107):132–136 (in Russ.).
11. Tumietto F., Posteraro B., Sanguinetti M. Looking for appropriateness in the cure of mixed vaginitis: the role of fenticonazole as an empiric treatment. Future Microbiol. 2019;14:1349–1355. DOI: 10.2217/fmb-2019-0189.
12. Zilberberg N.V., Grekova Yu.N., Levchik N.K. et al. Principles of therapy of bacterial vaginosis associated with Gardnerella vaginalis and Atopobium vaginae in women of reproductive age. Gynecology, Obstetrics and Perinatology. 2018;17(6):19–25 (in Russ.). DOI: 10.20953/1726-1678-2018-6.
13. Muzny C., Łaniewski P., Schwebke J., Herbst-Kralovetz M. Host-vaginal microbiota interactions in the pathogenesis of bacterial vaginosis. Curr Opin Infect Dis. 2020;33(1):59–65. DOI: 10.1097/QCO.0000000000000620.
14. Malova I.O., Afanasyeva I.G. Bacterial Vaginosis: Is there an alternative to traditional drugs? Meditsinsky Sovet. 2019;(7):93–103 (in Russ.). DOI: 10.21518/2079-701X-2019-7-93-103.
15. Abdul-Aziz M., Mahdy M.A.K., Abdul-Ghani R. et al. Bacterial Vaginosis, Vulvovaginal Candidiasis and Trichomonal Vaginitis Among Reproductive-Aged Women Seeking Primary Healthcare in Sana'a City, Yemen. BMC Infect Dis. 2019;19(1):879. DOI: 10.1186/s12879-019-4549-3.
16. Ng B., Chuah J., Cheah F. et al. Maternal and fetal outcomes of pregnant women with bacterial vaginosis. Front Surg. 2023;10:1084867. DOI: 10.3389/fsurg.2023.1084867.
17. Pentikis H., Adetoro N., Tipping D., Levy S. An Integrated Efficacy and Safety Analysis of Single-Dose Secnidazole 2 g in the Treatment of Bacterial Vaginosis. Reprod Sci. 2020;27(2):523–528. DOI: 10.1007/s43032-019-00048-x.
18. Cohen C., Wierzbicki M., French A. et al. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med. 2020;382(20):1906–1915. DOI: 10.1056/NEJMoa1915254.
19. Kamga Y., Ngunde J., Akoachere J.K.T. Prevalence of Bacterial Vaginosis and Associated Risk Factors in Pregnant Women Receiving Antenatal Care at the Kumba Health District (KHD), Cameroon. BMC Pregnancy Childbirth. 2019;19(1):166. DOI: 10.1186/s12884-019-2312-9.
20. Podzolkova N.M., Nikitina T.I. Comparative evaluation of various treatment regimens for patients with bacterial vaginosis and nonspecific vulvovaginitis. Russian Bulletin of Obstetrician-Gynecologist. 2012;12(5):72–78 (in Russ.).
21. Morrill S., Gilbert N., Lewis A. Gardnerella vaginalis as a Cause of Bacterial Vaginosis: Appraisal of the Evidence From in vivo Models. Front Cell Infect Microbiol. 2020;10:168. DOI: 10.3389/fcimb.2020.00168.
22. Plummer E.L., Vodstrcil L.A., Doyle M. et al. A Prospective, Open-Label Pilot Study of Concurrent Male Partner Treatment for Bacterial Vaginosis. mBio. 2021;12(5):e0232321. DOI: 10.1128/mBio.02323-21.
23. Abd El Aziz M., Sharifipour F., Abedi P. et al. Secnidazole for treatment of bacterial vaginosis: a systematic review. BMC Womens Health. 2019;19(1):121. DOI: 10.1186/s12905-019-0822-2.
24. Schwebke J., Morgan F., Koltun W., Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017;217(6):678.e1–678.e9. DOI: 10.1016/j.ajog.2017.08.017.
25. Hillier S., Nyirjesy P., Waldbaum A. Secnidazole treatment of bacterial vaginosis: a randomized controlled study. Obstet Gynecol. 2017;130(2):379–386. DOI: 10.1097/AOG.0000000000002135.
26. Muzny C., Kardas P. A Narrative Review of Current Challenges in the Diagnosis and Management of Bacterial Vaginosis. Sex Transm Dis. 2020;47(7):441–446. DOI: 10.1097/OLQ.0000000000001178.
27. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74. DOI: 10.1097/00005650-198601000-00007.
28. Mitikhin V.G, Solokhina T.A., Alieva L.M. Innovative technology for assessing the level of compliance of mentally ill people. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2021;121(9):72–78 (in Russ.). DOI: 10.17116/jnevro202112109172.
29. Nurainiwati S., Ma'roef M., Pravitasari D., Putra P. Effectivity and efficacy probiotics for Bacterial Vaginosis treatments: Meta-analysis. Infect Dis Model. 2022;7(4):597–604. DOI: 10.1016/j.idm.2022.09.001.
30. Amaya-Guio J., Viveros-Carreno D.A., Sierra-Barrios E.M. et al. Antibiotic treatment for the sexual partners of women with bacterial vaginosis. Cochrane Database Syst Rev. 2016;10(10):CD011701. DOI: 10.1002/14651858.CD011701.pub2.
31. Nyirjesy P., Schwebke J. Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment. Future Microbiol. 2018;13:507–524. DOI: 10.2217/fmb-2017-0270.
32. SOLOSEC (secnidazole) oral granules. Initial U.S. Approval: 2017. (Electronic resourсe.) URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209363s000lbl.pdf (аccess date: 12.03.2023).
33. Thulkar J., Kriplani A., Agarwal N. A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis. Indian J Pharmacol. 2012;44(2):243–245. DOI: 10.4103/0253-7613.93859.
34. Saraçoğlu F., Göl K., Sahin I. et al. Treatment of bacterial vaginosis with oral or vaginal ornidazole, secnidazole and metronidazole. Int J Gynaecol Obstet. 1998;62(1):59–61. DOI: 10.1016/s0020-7292(98)00029-0.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать